STRESS-L is now re-open to recruitment
We are delighted to announce STRESS-L has received confirmation to restart recruitment. Thank you to all of our recruitment sites for your patience whilst we have prepared for the restart. We very much look forward to working with you again shortly.
The STRESS-L trial team will contact each site individually to provide the green light to locally restart recruitment.
Please do not restart screening or recruitment until you have received this greenlight.
Further details of requirements for the restart including refresher training can be found here.
All trial documentation for site staff has been uploaded to the website and can be downloaded here
Managed Recovery Programme
STRESS-L is now part of the Managed Recovery Programme as it has been identified as an important high priority critical care study for sites to deliver. This programme ensures targeted support from the CRN in collaboration with R&D departments is available to help sites recruit and open to the trial. If you are a site requiring further support to assist with capacity challenges or anything else please get in touch with the STRESS-L team to discuss this further. To read more about the programme please click here.
STRESS-L Investigator Meeting 14 June 2021
We would like to say a huge thank you to everyone who attended the STRESS-L virtual Investigator Meeting. We hope you found the meeting informative and useful to help with recruitment and answer any questions you might have. A special thank you to Prof Ingeborg Welters (PI) at Royal Liverpool and Dr Sam Waddy (PI) at Derriford Hospital for your insight and top tips for recruiting to the trial. We would also like to thank our PPI representative Lee Bettles for being honest and open regarding his real life experience of having sepsis and why STRESS-L matters. For anyone who was unable to attend the meeting a record of the meeting can be downloaded here.
Stress-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)
Chief Investigator: Dr Tony Whitehouse
Sponsor: University Hospitals Birmingham NHS Foundation Trust
Registration Number: ISRCTN12600919
Septic shock (sometimes called blood poisoning) is a life-threatening condition caused by severe infection. For reasons still poorly understood, in some patients, the inflammation in their system doesn’t reduce after an infection. Instead of fighting the infection, an ongoing inflammatory state results in widespread injury to the body and failure of normal functioning of the body’s vital organs, such as the lungs, heart, brain and kidneys. A common indicator of septic shock is a very low blood pressure that does not improve, even when treated with an intravenous fluid drip, which is the usual treatment for very low blood pressure.
For many years, we have routinely used in clinical practice a group of drugs known as ‘catecholamines’ to increase the patient’s blood pressure back to normal. The objective is that this will help their vital organs to function properly and to recover. The most commonly used catecholamine is noradrenaline, a synthetic form of a hormone produced by the body to deal with stressful situations. However, noradrenaline does carry side-effects when given at high doses and for extended periods of time, including adverse effects on the heart, the immune system and the patient’s metabolism. Thus, the drug treatment itself, which is given to help the body’s own production of these hormones, may achieve the short-term goal of increasing blood pressure, but at the possible expense of more damage to the body. The use of catecholamines is therefore being questioned.
In 2013, a doctor called Morelli showed that when patients were being treated with a very high dose of noradrenaline, and were also given a beta blocker (a type of drug that reduces the heart rate), patients on average got better more often, more quickly. We propose to repeat their study in multiple (approx. 30-35) intensive care units throughout the UK to see if we can confirm the safety and benefits of using beta blockers. We are also going to take blood samples to measure effects of the beta blocker on the patient’s immune system, metabolism and heart function so that we may better understand how it works. We also propose to store blood samples for analysis of the genes and proteins that may predispose patients to become so severely septic and to identify those who respond better to beta blocker therapy.
The primary outcome will be the mean SOFA score between treatment groups over the first 14 days from entry to the trial and whilst in ICU.
The trial will close 31 August 2021.
Total patients recruited: 119
Sites active: 23
The STRESS-L trial are currently working closely with sites to locally restart recruitment following the COVID-19 pandemic.
Click here to view of list of sites.
Click here to read restart FAQ's
Tel: 07385 029 213
Warwick Clinical Trials Unit
Warwick Medical School
University of Warwick
Gibbet Hill Road